What are the known side effects and drug interactions of ivermectin in humans?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Ivermectin is an anti‑parasitic medicine with a long safety record at approved doses but it can cause common, usually mild effects such as rash, nausea, dizziness and fatigue and — rarely — serious neurological, hepatic or allergic reactions that have led to hospitalization in some cases [1] [2] [3]. Drug–drug interactions are uncommon for typical uses but important exceptions exist: ivermectin’s brain‑penetration is limited by P‑glycoprotein (mdr‑1), so genetic loss of that transporter or co‑medications that alter CYP3A4/P‑glycoprotein activity or co‑infection with Loa loa can precipitate severe neurotoxicity [4] [5] [1].
1. Common and expected side effects clinicians track
At standard human doses the most frequently reported reactions are rash, peripheral edema, headache, dizziness, asthenia (weakness), nausea and gastrointestinal symptoms such as diarrhea, with many product monographs and drug information sites listing these as the typical adverse effects to counsel about [1] [6] [7]. Multiple clinical references note drowsiness, temporary energy loss, and transient skin reactions after oral or topical use, and public drug databases advise patients not to drive until they know how ivermectin affects them [2] [8] [6].
2. Serious but uncommon harms: neurologic, hepatic and allergic events
Serious events documented in case reports and surveillance include encephalopathy, confusion, ataxia, seizures, stupor or coma, along with severe skin reactions and cases of hepatitis; these outcomes are rare relative to widespread therapeutic use but have required hospitalization and intensive care in reported case series and reviews [9] [5] [7]. Pharmacovigilance studies and reviews emphasize that encephalopathic reactions are especially reported in persons with very high Loa loa microfilarial loads after mass treatment campaigns, and that while rare in other settings, serious neurologic events have been observed and warrant caution [5] [10].
3. Pharmacology explains many interactions and vulnerabilities
Ivermectin is kept out of the central nervous system in most people by P‑glycoprotein (the product of mdr‑1), so genetic loss‑of‑function variants or conditions that compromise the blood‑brain barrier can allow CNS accumulation and toxicity; animal models and human case analyses support this mechanism [4] [1]. In vitro data and some reports show interactions with CYP3A4 substrates and several antiretroviral drugs, and labeling and reviews note that co‑administration with medicines affecting CYP3A4 or P‑glycoprotein could alter ivermectin exposure or vice versa — although routine labeling does not list broad prohibitions, clinicians are advised to monitor or adjust therapy as needed [4] [11] [6].
4. Notable interacting medications and substances to watch
Authoritative sources flag blood thinners such as warfarin as an interaction of practical importance that may require monitoring because ivermectin can affect INR or bleeding risk, and clinicians are also advised to review all prescription, OTC, herbal and supplement products since interactions range from pharmacodynamic to pharmacokinetic [8] [6]. Alcohol is commonly reported to increase dizziness and sleepiness when combined with ivermectin and many drug summaries caution that drinking may amplify those adverse effects [6] [8] [7]. Reports and systematic reviews also raise potential interactions with certain antiretroviral agents based on in vitro findings and case reports, recommending vigilance though large randomized interaction trials are limited [4].
5. Dose, context and misuse change the risk picture
Safety data and regulatory warnings underline that approved human formulations at standard weight‑based doses are generally safe, but overdoses — including ingestion of veterinary formulations intended for animals — have produced severe toxicity, and misuse during the COVID‑19 pandemic led to increased hospitalizations for confusion, hypotension and seizures [6] [9] [12]. Public health agencies and drug monographs explicitly warn against using animal ivermectin products in people and emphasize obtaining prescriptions from legitimate sources [6] [12].
6. What remains uncertain and how clinicians manage risk
Gaps remain: the exact frequency of rare severe neurologic events outside Loa loa endemic settings is not fully quantified and the clinical significance of some in‑vitro drug interactions (for example with certain antiretrovirals) needs more clinical study, so guidance relies on case reports, pharmacology, and pharmacovigilance data rather than large randomized interaction studies [4] [5]. Until stronger evidence accumulates, major sources recommend weight‑based dosing for approved indications, counseling on common side effects, monitoring when combined with warfarin or drugs affecting CYP3A4/P‑glycoprotein, and immediate evaluation for neurologic or allergic symptoms [1] [11] [8].